Global Myelodysplastic Syndrome (MDS) Treatment Market Insights, Forecast


 MDPH0K6SVXTM |  Pharma, Healthcare, Life Sciences & Medical |  Feb 05, 2019  |  119



Myelodysplastic (MDS) syndrome is a type of bone marrow disorder, where bone marrow is unable to produce healthy and mature blood cells. The immature blood cells called as blasts, get stored in the bone marrow and blood and obstruct the natural function of the hematological system which results in depletion of healthy red blood cells, platelets, and white blood cells. Myelodysplastic syndrome is usually seen in geriatric population and more often in older men than women. This syndrome is characterized by certain chromosomal mutations in Janus Kinase gene which include deletion of q arm in one or more chromosomes and complete deletion of chromosome 5 or 7 and an extra copy of chromosome 8.
According to the American Cancer Society, the incidence rate for myelodysplastic syndrome is 13,000 new cases each year which happens at a rate of 4.8 cases per 100,000 people. This trend is heavily affected or rather influenced by the average age of the population which, according to the World Health Organization (WHO), is increasing and is expected to double from 12% to 22% between 2015 and 2050.
The global Myelodysplastic Syndrome (MDS) Treatment market is valued at 2210 million US$ in 2018 and will reach 5760 million US$ by the end of 2025, growing at a CAGR of 12.7% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Myelodysplastic Syndrome (MDS) Treatment market based on company, product type, end user and key regions.

This report studies the global market size of Myelodysplastic Syndrome (MDS) Treatment in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Myelodysplastic Syndrome (MDS) Treatment in these regions.
This research report categorizes the global Myelodysplastic Syndrome (MDS) Treatment market by top players/brands, region, type and end user. This report also studies the global Myelodysplastic Syndrome (MDS) Treatment market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Novartis AG
Celgene Corporation
Otsuka Pharmaceutical Co., Ltd
Sandoz Inc
Dr Reddys Laboratories Limited
Pharmascience Inc
Accord Healthcare Ltd
Mylan N.V.

Market size by Product
Azacitidine
Lenalidomide
Decitabine
Deferasirox
Market size by End User
Refractory cytopenia with unilineage dysplasia
Refractory anemia with ringed sideroblasts
Others

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Myelodysplastic Syndrome (MDS) Treatment market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Myelodysplastic Syndrome (MDS) Treatment market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Myelodysplastic Syndrome (MDS) Treatment companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Myelodysplastic Syndrome (MDS) Treatment submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Myelodysplastic Syndrome (MDS) Treatment are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Myelodysplastic Syndrome (MDS) Treatment market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Study Coverage
    1.1  Myelodysplastic Syndrome (MDS) Treatment Product
    1.2 Market Segments
    1.3 Key Manufacturers Covered
    1.4 Market by Type
        1.4.1 Global Myelodysplastic Syndrome (MDS) Treatment Market Size Growth Rate by Product
        1.4.2 Azacitidine
        1.4.3 Lenalidomide
        1.4.4 Decitabine
        1.4.5 Deferasirox
    1.5 Market by End User
        1.5.1 Global Myelodysplastic Syndrome (MDS) Treatment Market Size Growth Rate by End User
        1.5.2 Refractory cytopenia with unilineage dysplasia
        1.5.3 Refractory anemia with ringed sideroblasts
        1.5.4 Others
    1.6 Study Objectives
    1.7 Years Considered

2 Executive Summary
    2.1 Global Myelodysplastic Syndrome (MDS) Treatment Market Size
        2.1.1 Global Myelodysplastic Syndrome (MDS) Treatment Revenue 2014-2025
        2.1.2 Global Myelodysplastic Syndrome (MDS) Treatment Sales 2014-2025
    2.2 Myelodysplastic Syndrome (MDS) Treatment Growth Rate by Regions
        2.2.1 Global Myelodysplastic Syndrome (MDS) Treatment Sales by Regions
        2.2.2 Global Myelodysplastic Syndrome (MDS) Treatment Revenue by Regions

3 Breakdown Data by Manufacturers
    3.1 Myelodysplastic Syndrome (MDS) Treatment Sales by Manufacturers
        3.1.1 Myelodysplastic Syndrome (MDS) Treatment Sales by Manufacturers
        3.1.2 Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Manufacturers
        3.1.3 Global Myelodysplastic Syndrome (MDS) Treatment Market Concentration Ratio (CR5 and HHI)
    3.2 Myelodysplastic Syndrome (MDS) Treatment Revenue by Manufacturers
        3.2.1 Myelodysplastic Syndrome (MDS) Treatment Revenue by Manufacturers (2014-2019)
        3.2.2 Myelodysplastic Syndrome (MDS) Treatment Revenue Share by Manufacturers (2014-2019)
    3.3 Myelodysplastic Syndrome (MDS) Treatment Price by Manufacturers
    3.4 Myelodysplastic Syndrome (MDS) Treatment Manufacturing Base Distribution, Product Types
        3.4.1 Myelodysplastic Syndrome (MDS) Treatment Manufacturers Manufacturing Base Distribution, Headquarters
        3.4.2 Manufacturers Myelodysplastic Syndrome (MDS) Treatment Product Type
        3.4.3 Date of International Manufacturers Enter into Myelodysplastic Syndrome (MDS) Treatment  Market
    3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product
    4.1 Global Myelodysplastic Syndrome (MDS) Treatment Sales by Product
    4.2 Global Myelodysplastic Syndrome (MDS) Treatment Revenue by Product
    4.3 Myelodysplastic Syndrome (MDS) Treatment Price by Product

5 Breakdown Data by End User
    5.1 Overview
    5.2 Global Myelodysplastic Syndrome (MDS) Treatment Breakdown Data by End User

6 North America
    6.1 North America Myelodysplastic Syndrome (MDS) Treatment by Countries
        6.1.1 North America Myelodysplastic Syndrome (MDS) Treatment Sales by Countries
        6.1.2 North America Myelodysplastic Syndrome (MDS) Treatment Revenue by Countries
        6.1.3 United States
        6.1.4 Canada
        6.1.5 Mexico
    6.2 North America Myelodysplastic Syndrome (MDS) Treatment by Product
    6.3 North America Myelodysplastic Syndrome (MDS) Treatment by End User

7 Europe
    7.1 Europe Myelodysplastic Syndrome (MDS) Treatment by Countries
        7.1.1 Europe Myelodysplastic Syndrome (MDS) Treatment Sales by Countries
        7.1.2 Europe Myelodysplastic Syndrome (MDS) Treatment Revenue by Countries
        7.1.3 Germany
        7.1.4 France
        7.1.5 UK
        7.1.6 Italy
        7.1.7 Russia
    7.2 Europe Myelodysplastic Syndrome (MDS) Treatment by Product
    7.3 Europe Myelodysplastic Syndrome (MDS) Treatment by End User

8 Asia Pacific
    8.1 Asia Pacific Myelodysplastic Syndrome (MDS) Treatment by Countries
        8.1.1 Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Sales by Countries
        8.1.2 Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Revenue by Countries
        8.1.3 China
        8.1.4 Japan
        8.1.5 Korea
        8.1.6 India
        8.1.7 Australia
        8.1.8 Indonesia
        8.1.9 Malaysia
        8.1.10 Philippines
        8.1.11 Thailand
        8.1.12 Vietnam
        8.1.13 Singapore
    8.2 Asia Pacific Myelodysplastic Syndrome (MDS) Treatment by Product
    8.3 Asia Pacific Myelodysplastic Syndrome (MDS) Treatment by End User

9 Central & South America
    9.1 Central & South America Myelodysplastic Syndrome (MDS) Treatment by Countries
        9.1.1 Central & South America Myelodysplastic Syndrome (MDS) Treatment Sales by Countries
        9.1.2 Central & South America Myelodysplastic Syndrome (MDS) Treatment Revenue by Countries
        9.1.3 Brazil
    9.2 Central & South America Myelodysplastic Syndrome (MDS) Treatment by Product
    9.3 Central & South America Myelodysplastic Syndrome (MDS) Treatment by End User

10 Middle East and Africa
    10.1 Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment by Countries
        10.1.1 Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Sales by Countries
        10.1.2 Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Revenue by Countries
        10.1.3 GCC Countries
        10.1.4 Turkey
        10.1.5 Egypt
        10.1.6 South Africa
    10.2 Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment by Product
    10.3 Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment by End User

11 Company Profiles
    11.1 Novartis AG
        11.1.1 Novartis AG Company Details
        11.1.2 Company Business Overview
        11.1.3 Novartis AG Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Gross Margin (2014-2019)
        11.1.4 Novartis AG Myelodysplastic Syndrome (MDS) Treatment Products Offered
        11.1.5 Novartis AG Recent Development
    11.2 Celgene Corporation
        11.2.1 Celgene Corporation Company Details
        11.2.2 Company Business Overview
        11.2.3 Celgene Corporation Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Gross Margin (2014-2019)
        11.2.4 Celgene Corporation Myelodysplastic Syndrome (MDS) Treatment Products Offered
        11.2.5 Celgene Corporation Recent Development
    11.3 Otsuka Pharmaceutical Co., Ltd
        11.3.1 Otsuka Pharmaceutical Co., Ltd Company Details
        11.3.2 Company Business Overview
        11.3.Otsuka Pharmaceutical Co., Ltd Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Gross Margin (2014-2019)
        11.3.4 Otsuka Pharmaceutical Co., Ltd Myelodysplastic Syndrome (MDS) Treatment Products Offered
        11.3.5 Otsuka Pharmaceutical Co., Ltd Recent Development
    11.4 Sandoz Inc
        11.4.1 Sandoz Inc Company Details
        11.4.2 Company Business Overview
        11.4.3 Sandoz Inc Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Gross Margin (2014-2019)
        11.4.4 Sandoz Inc Myelodysplastic Syndrome (MDS) Treatment Products Offered
        11.4.5 Sandoz Inc Recent Development
    11.5 Dr Reddys Laboratories Limited
        11.5.1 Dr Reddys Laboratories Limited Company Details
        11.5.2 Company Business Overview
        11.5.3 Dr Reddys Laboratories Limited Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Gross Margin (2014-2019)
        11.5.4 Dr Reddys Laboratories Limited Myelodysplastic Syndrome (MDS) Treatment Products Offered
        11.5.5 Dr Reddys Laboratories Limited Recent Development
    11.6 Pharmascience Inc
        11.6.1 Pharmascience Inc Company Details
        11.6.2 Company Business Overview
        11.6.3 Pharmascience Inc Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Gross Margin (2014-2019)
        11.6.4 Pharmascience Inc Myelodysplastic Syndrome (MDS) Treatment Products Offered
        11.6.5 Pharmascience Inc Recent Development
    11.7 Accord Healthcare Ltd
        11.7.1 Accord Healthcare Ltd Company Details
        11.7.2 Company Business Overview
        11.7.3 Accord Healthcare Ltd Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Gross Margin (2014-2019)
        11.7.4 Accord Healthcare Ltd Myelodysplastic Syndrome (MDS) Treatment Products Offered
        11.7.5 Accord Healthcare Ltd Recent Development
    11.8 Mylan N.V.
        11.8.1 Mylan N.V. Company Details
        11.8.2 Company Business Overview
        11.8.3 Mylan N.V. Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Gross Margin (2014-2019)
        11.8.4 Mylan N.V. Myelodysplastic Syndrome (MDS) Treatment Products Offered
        11.8.5 Mylan N.V. Recent Development

12 Future Forecast
    12.1 Myelodysplastic Syndrome (MDS) Treatment Market Forecast by Regions
        12.1.1 Global Myelodysplastic Syndrome (MDS) Treatment Sales Forecast by Regions 2019-2025
        12.1.2 Global Myelodysplastic Syndrome (MDS) Treatment Revenue Forecast by Regions 2019-2025
    12.2 Myelodysplastic Syndrome (MDS) Treatment Market Forecast by Product
        12.2.1 Global Myelodysplastic Syndrome (MDS) Treatment Sales Forecast by Product 2019-2025
        12.2.2 Global Myelodysplastic Syndrome (MDS) Treatment Revenue Forecast by Product 2019-2025
    12.3 Myelodysplastic Syndrome (MDS) Treatment Market Forecast by End User
    12.4 North America Myelodysplastic Syndrome (MDS) Treatment Forecast
    12.5 Europe Myelodysplastic Syndrome (MDS) Treatment Forecast
    12.6 Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Forecast
    12.7 Central & South America Myelodysplastic Syndrome (MDS) Treatment Forecast
    12.8 Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
    13.1 Market Opportunities and Drivers
    13.2 Market Challenges
    13.3 Market Risks/Restraints
    13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis
    14.1 Value Chain Analysis
    14.2 Myelodysplastic Syndrome (MDS) Treatment Customers
    14.3 Sales Channels Analysis
        14.3.1 Sales Channels
        14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
    16.1 Research Methodology
        16.1.1 Methodology/Research Approach
        16.1.2 Data Source
    16.2 Author Details
    16.3 Disclaimer

Write Us - Contact us


Jot us a note and we’ll get back to you as quickly as possible

Only corporate email-id will be given priority. Please do not provide Gmail,Yahoo,Hotmail,Outlook,Icloud,MSN,Rediff,Naver,QQ,163,123,Yandex, Protonmail,Yopmail,Hanmail,@me.com,@live.com,@mail.com,@gmx.com









Purchase options

Single User $ 3900.00
Enterprise User $ 7800.00